Keyphrases
Acute Lymphoblastic Leukemia
100%
Antibody Conjugates
33%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
33%
BCP-ALL
66%
Calicheamicin
66%
CAR T-cell Therapy
33%
CD22
100%
Event-free Survival
33%
Gemtuzumab Ozogamicin
100%
Minimal Residual Disease
66%
Overall Response Rate
100%
Overall Survival
33%
Pediatric Patients
100%
Phase II Trial
100%
Relapsed or Refractory
33%
Single-stage
33%
Sinusoidal Obstruction Syndrome
66%
Stage Design
33%
Surface Expression
33%
Survivors
33%
Medicine and Dentistry
Acute B-Cell Lymphoblastic Leukemia
50%
Acute Lymphoblastic Leukemia
100%
Antibody Conjugate
50%
Calicheamicin
100%
CAR T-cell therapy
50%
Event Free Survival
50%
In Vitro
50%
Inotuzumab Ozogamicin
100%
Internalization
50%
Minimal Residual Disease
100%
Overall Survival
50%
Pediatrics Patient
100%
Phase II Trials
100%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Antibody Conjugate
50%
Calicheamicin
100%
Event Free Survival
50%
Inotuzumab Ozogamicin
100%
Minimal Residual Disease
100%
Overall Survival
50%
Phase II Trials
100%
Syndrome
100%
Immunology and Microbiology
Antibody Conjugate
33%
B Cell
33%
CD22
100%
Chimeric Antigen Receptor T-Cell
33%
Event Free Survival
33%
Inotuzumab Ozogamicin
100%
Internalization
33%
Overall Survival
33%